MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $138.68M
Last updated: Nov 17, 2026 at 4:15 PM ET
MacroGenics Inc (MGNX) Stock Chart
MacroGenics (MGNX) has a latest price of $2.05 on Nov 17, 2026, 59.6% below its 52-week high of $5.08. Its price rose 36.7% over the past 12 months. The month-end price fell 89.9% over the 10 years through Oct 2026, a compound annual decline of 20.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $32.36 in Apr 2021 and its lowest $1.21 in Jun 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart MGNX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for MGNX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 50.8%, and over 6 months it fell 54.6%. The month-end price fell 54.0% over the 3 years through Oct 2026, a compound annual decline of 22.8%.
| Period | Change |
|---|---|
| 1 month | -38.4% |
| 3 months | -50.8% |
| 6 months | -54.6% |
| 12 months | +36.7% |
| 12 months, with dividends | +36.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -54.0% | -22.8% |
| 5 years | -87.7% | -34.2% |
| 10 years | -89.9% | -20.5% |
Price by Year
Its best calendar year was 2020, when the price rose 110.1%, and its weakest was 2024, when it fell 66.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.40 | +49.1% |
| 2025 | $1.61 | -50.5% |
| 2024 | $3.25 | -66.2% |
| 2023 | $9.62 | +43.4% |
| 2022 | $6.71 | -58.2% |
| 2021 | $16.05 | -29.8% |
| 2020 | $22.86 | +110.1% |
| 2019 | $10.88 | -14.3% |
| 2018 | $12.70 | -33.2% |
| 2017 | $19.00 | -7.0% |
Trading Range
The price is 36.7% below its 50-day average of $3.24 and 40.5% below its 200-day average of $3.45.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.05 | |
| 52-week high | $5.08 | -59.6% |
| 52-week low | $1.32 | +55.3% |
| 50-day average | $3.24 | -36.7% |
| 200-day average | $3.45 | -40.5% |
Price Risk
Over 3 years, its largest fall from a peak was 95.1%.
| Measure | Value |
|---|---|
| 1-year beta | 1.08 |
| Largest fall, 1 year | -57.8% |
| Largest fall, 3 years | -95.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About MGNX
What is MGNX's 1-year price change?
MacroGenics's price rose 36.7% over the past 12 months. With dividends included, the 12-month total return was 36.7%.
What is MGNX's 5-year price change?
MacroGenics's month-end price fell 87.7% over the 5 years through Oct 2026, a compound annual decline of 34.2%. These figures leave out dividends.
What is MGNX's 52-week high and low?
MacroGenics's 52-week high is $5.08 and its 52-week low is $1.32. Its latest price of $2.05 on Nov 17, 2026 is 59.6% below the high.
What is MGNX's beta?
MacroGenics's 1-year beta against the S&P 500 is 1.08, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 57.8%.
Is the MGNX chart free?
Yes. Advanced Charting for MGNX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
MGNX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts